نتائج البحث 331-340 من 15099 لعملية البحث عن Severe hyponatraemia
Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung ...
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore ...
... severe residual upper-extremity motor impairment due to stroke. A Study to Evaluate Awake vs. Asleep Spine Surgery. Jacksonville, Fla. Patients undergoing ...
In particular, we plan to bank blood and bone marrow from patients with newly diagnoses or relapsed acute leukemia (AML or ALL) for future biological studies.
... severe residual upper-extremity motor impairment due to stroke. A Study To Create A Registry Of Non-Fusion Spinal Deformity Correction In Adolescent ...
... chronic pain, to those with chronic pain alone, to that of healthy controls; to evaluate whether there is a change in functional connectivity following ...
To evaluate the safety and efficacy of Siegel™ TAVR System in the treatment of subjects with symptomatic severe native aortic stenosis. BoxX-NoAF Clinical Trial.
Dines, M.D.. Nephrologist. Rochester, MN. مناطق التركيز: Chronic kidney disease, High blood pressure, Kidney stone, Acute kidney inury, Hyponatremia, ...
... chronic ischemic stroke. Acute Modulation of Stereotyped High-Frequency Oscillations. Rochester, Minn. The purpose of this study is to do data collection of ...
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or ...
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.